Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Wegovy's Precarious Position: 3 Drugs Most Likely to Dethrone Novo Nordisk's Blockbuster Obesity Drug

TheMotleyFool

0 0

Wegovy's Precarious Position: 3 Drugs Most Likely to Dethrone Novo Nordisk's Blockbuster Obesity Drug: https://g.foolcdn.com/editorial/images/780375/ozempic.jpg

Novo Nordisk's (NYSE: NVO) Wegovy currently reigns as the king of the obesity drug market. It generated roughly $4.5 billion in sales last year and will likely rake in even more in 2024.

But note the use of the word "currently." Wegovy's market-topping position is precarious. Here are three drugs most likely to dethrone Novo Nordisk's blockbuster drug.

Eli Lilly (NYSE: LLY) won U.S. regulatory approval for Zepbound in helping patients lose weight in November 2023. In the first quarter of 2024, the sales for Lilly's obesity drug topped $517 million.

Source Fool.com

Like: 0

VKTX

Share